| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 244K | +48% |
| Operating Income | -8.7MM | +1% |
| Operating Expenses | 9MM | +2% |
| Net Income | - | - |
| R&D | 4.5MM | -2% |
| G&A | 2.5MM | -2% |
| Marketing | 1.9MM | +21% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT OPERATIONAL UPDATES & 2023 FINANCIAL RESULTS Commercialization of Nu.Q Vet Continues During 2023, Volition Veterinary (NYSE:VNRX) continued to expand its distribution network through new supply agreements. The Nu.Q Vet Cancer Test is currently available in • the U.S. (initial product launch in November 2020 through direct
VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript March 26, 2024 VolitionRx Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full […]
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023. Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full year 2023, in addition to providing a business update. Details of this event can also be found below.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these biotech stocks that will provide high retu
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.